HomeCompareMDCLF vs EPRT

MDCLF vs EPRT: Dividend Comparison 2026

MDCLF yields 5.82% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $34.0K in total portfolio value· pulled ahead in Year 3
10 years
MDCLF
MDCLF
● Live price
5.82%
Share price
$34.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$842.73
Full MDCLF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — MDCLF vs EPRT

📍 EPRT pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDCLFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDCLF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDCLF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDCLF
Annual income on $10K today (after 15% tax)
$494.33/yr
After 10yr DRIP, annual income (after tax)
$716.32/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,198.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDCLF + EPRT for your $10,000?

MDCLF: 50%EPRT: 50%
100% EPRT50/50100% MDCLF
Portfolio after 10yr
$46.4K
Annual income
$6,841.72/yr
Blended yield
14.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

MDCLF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
5.5
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDCLF buys
0
EPRT buys
0
No recent congressional trades found for MDCLF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDCLFEPRT
Forward yield5.82%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$29.3K$63.4K
Annual income after 10y$842.73$12,840.73
Total dividends collected$7.2K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: MDCLF vs EPRT ($10,000, DRIP)

YearMDCLF PortfolioMDCLF Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,282$581.56$11,205$505.18+$77.00MDCLF
2$12,684$613.17$12,672$682.46+$12.00MDCLF
3← crossover$14,217$644.32$14,490$930.48$273.00EPRT
4$15,887$674.91$16,786$1,282.69$899.00EPRT
5$17,704$704.85$19,753$1,791.56$2.0KEPRT
6$19,677$734.08$23,677$2,541.64$4.0KEPRT
7$21,817$762.53$29,008$3,672.99$7.2KEPRT
8$24,134$790.14$36,463$5,425.08$12.3KEPRT
9$26,641$816.89$47,238$8,221.57$20.6KEPRT
10$29,348$842.73$63,385$12,840.73$34.0KEPRT

MDCLF vs EPRT: Complete Analysis 2026

MDCLFStock

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

Full MDCLF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this MDCLF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDCLF vs SCHDMDCLF vs JEPIMDCLF vs OMDCLF vs KOMDCLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.